To capture cancer cells with a partial EMT program, multiple mesenchymal markers have been used for immunolabeling of lineage‐tagged cancer cells, which included α‐smooth muscle actin (αSMA), Fsp1 (S100A4), Zeb1, and vimentin (Trimboli et al, 2008; Rhim et al, 2012; Fischer et al, 2015; Zheng et al, 2015; Aiello et al, 2016; Zhao et al, 2016). This evidence concerns the gene S100A4 and cancer.